ArticleOncotarget2017
Comparison of isolation platforms for detection of circulating renal cell carcinoma cells.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 45 citations in OpenAlex.
- Dynamic changes of different phenotypic and genetic circulating tumor cells as a biomarker for evaluating the prognosis of RCC.Cancer biology & therapy · 2019Trial
- Performance and pilot clinical validation of MALDITEC-CTC: a circulating tumor cell detection platform using whole-cell MALDI-TOF MS fingerprinting in osteosarcoma.Cancer cell international · 2026Article
- Identification of epithelial, mesenchymal, and platelet-associated circulating tumour cells with translational implications in oral squamous cell carcinoma.Scientific reports · 2026Article
- Repurposing Artesunate to Combat Progression and Metastasis via Targeting Circulating Tumor Cells.Oncology research · 2026Article
- Automated Analysis of Liquid Biopsy Using Deep Learning: Detecting Circulating Tumor Cells and Cancer-Associated Fibroblasts.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Establishing cM0 (i+) stage criteria in localized renal cell carcinoma based on postoperative circulating tumor cells monitoring.BMC cancer · 2025Article
- Article
- Clinical applications of circulating tumor cells in patients with solid tumors.Clinical & experimental metastasis · 2024Review
- The integrated on-chip isolation and detection of circulating tumour cells.Sensors & diagnostics · 2024Review
- A micropillar array-based microfluidic chip for label-free separation of circulating tumor cells: The best micropillar geometry?Journal of advanced research · 2023Article
- Comparative analysis of EpCAM high-expressing and low-expressing circulating tumour cells with regard to their clonal relationship and clinical value.British journal of cancer · 2023Article
- Automatic detection of circulating tumor cells and cancer associated fibroblasts using deep learning.Scientific reports · 2023Article
- Characterizing the epithelial-mesenchymal transition status of circulating tumor cells in head and neck squamous cell carcinoma.Head & neck · 2022Article
- Article
- Detection and Characterization of Circulating Tumor Cells Using Imaging Flow Cytometry-A Perspective Study.Cancers · 2022Article
- Size-based isolation and detection of renal carcinoma cells from whole blood.Molecular and clinical oncology · 2022Article
- Continuous centrifugal microfluidics (CCM) isolates heterogeneous circulating tumor cells via full automation.Theranostics · 2022Article
- Prognostic Role of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma: A Large, Multicenter, Prospective Trial.The oncologist · 2021Observational
- A microfluidic-based filtration system to enrich for bone marrow disseminated tumor cells from breast cancer patients.PloS one · 2021Article
- Current methodologies to detect circulating tumor cells: a focus on ovarian cancer.American journal of cancer research · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAnalysis of circulating tumor cells (CTCs) has progressed in several tumor entities. However, little is known about CTCs in clear cell renal cell carcinoma (ccRCC) patients. Aim of our studies was to build a stable
methodsWe compared the analytical performance of different CTC isolation methods with regard to yield and purity: EpCAM based enrichment, leukocyte depletion and size based enrichment. EpCAM and cytokeratin 8 (KRT8) as biomarker for CTCs expression were evaluated in ccRCC cell lines as well as clinical samples.
resultsWhile the EpCAM based approach failed to successfully isolate tumor cells, CD45 based approaches showed intermediate recovery rates. The cell-size based Parsortix system showed highest recovery rates. EpCAM expression was low or absent in most cell lines as well as in clinical samples, whereas KRT8 was detected as a potential biomarker in ccRCC.
conclusionEpCAM based approaches might miss a high number of CTCs due to low or absent expression of EpCAM in ccRCC, as shown in cell lines as well as in patient samples. We identified the cell-sized based, label independent Parsortix system to be the most effective recovery system for ccRCC CTCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.